| 產品名稱 |
pGEM-1-tRNA-1 |
| 商品貨號 |
B228924 |
| Designations |
pGEM-1-tRNA-1 |
| Species |
Homo sapiens, human |
| Depositors |
Biotechnology General Corp. |
| Applications |
To produce the authentic RNA (although lacking modified bases characteristic of the natural sequence), linearize the plasmid with BspMI and transcribe in vitro with T7 RNA polymerase. To produce an antisense transcript, linearize the plasmid with PvuII and transcribe in vitro with SP6 RNA polymerase. |
| Vector |
Construct size (kb): 2.900000095367432 |
| Insert |
DNA: Synthetic Insert lengths(kb): 0.07599999755620956 Gene product: RNA, transfer, lysine 3 [RNTK*] |
| Insert Size (kb) |
0.076 |
| Media |
ATCC® Medium 1227: LB Medium (ATCC medium 1065) with 50 mcg/ml ampicillin
|
| Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Comments |
Restriction digests of the clone give the following sizes (kb): HindIII/PvuII-- 3.0, 0.08; HindIII--3.0; PvuII--3.0; BglI--3.0; BglI/PvuII--1.7, 1.2. To produce the authentic RNA (although lacking modified bases characteristic of the natural sequence), linearize the plasmid with BspMI and transcribe in vitro with T7 RNA polymerase. To produce an antisense transcript, linearize the plasmid with PvuII and transcribe in vitro with SP6 RNA polymerase. |
| References |
Weiss R, et al. RNA tumor viruses: supplement and appendices. Cold Spring Harbor, NY: CSHL Press; 1985.
|
